In this context a predictive marker like PTTG-1 might be valuable to come to a decision on the still controversially discussed question if a patient with stage I-IIIA NSCLC should be treated with adjuvant chemotherapy or radiation after a histologically confirmed R0-resection of the tumor. Here, PTTG1 is linked to neoplasm.